
Nektar Therapeutics: updates and filings
Price
$32.54
November 19, 2026Market cap $1.1B
What Ploutos Investor adds for Nektar Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 8, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Regulation FD disclosureForm8-K
- Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 20, 2026Shares registered for employeesFormS-8
- Oct 1, 2026Regulation FD disclosureForm8-K
- Sep 28, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 25, 2026Other material eventsForm8-K
- Sep 8, 2026Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Shares registered for employeesFormS-8
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 5, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 8, 2026Material agreement entered, officer or director changeForm8-K
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Additional annual meeting materialFormDEFA14A
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 13, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 20, 2026 | S-8 | Shares registered for employees | Document |
| Oct 1, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 28, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 25, 2026 | 8-K | Other material events | Document |
| Sep 8, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | S-8 | Shares registered for employees | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 5, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 8, 2026 | 8-K | Material agreement entered, officer or director change | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Feb 14, 1996: every report, 8-K, meeting and letter. Of its other filings (937 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 63.
The full analysis
What do Nektar Therapeutics's filings show?
The filings are where every one of Nektar Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.